KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease

Seong Hee Kang; Hye Won Lee; Jeong Ju Yoo; Yuri Cho; Seung Up Kim; Tae Hee Lee; Byoung Kuk Jang; Sang Gyune Kim; Sang Bong Ahn; Haeryoung Kim; Dae Won Jun; Joon Il Choi; Do Seon Song; Won Kim; Soung Won Jeong; Moon Young Kim; Hong Koh; Sujin Jeong; Jin Woo Lee; Yong Kyun Cho

doi:10.3350/cmh.2021.0178

KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease

Seong Hee Kang, Hye Won Lee, Jeong Ju Yoo, Yuri Cho, Seung Up Kim, Tae Hee Lee, Byoung Kuk Jang, Sang Gyune Kim, Sang Bong Ahn, Haeryoung Kim, Dae Won Jun, Joon Il Choi, Do Seon Song, Won Kim, Soung Won Jeong, Moon Young Kim, Hong Koh, Sujin Jeong, Jin Woo Lee, Yong Kyun Cho

Research output: Contribution to journal › Article › peer-review

61 Citations (Scopus)

Original language	English
Pages (from-to)	363-401
Number of pages	39
Journal	Clinical and Molecular Hepatology
Volume	27
Issue number	3
DOIs	https://doi.org/10.3350/cmh.2021.0178
Publication status	Published - 2021 Jul

Bibliographical note

Funding Information:
Sang Bong Ahn has received grants from Hanwha, Samjin, Il-dong, and Hanmi.

Funding Information:
Tae Hee Lee is a speaker for Abbvie, Gilead, Samil Pharm and Yuhan. He has received a research grant from Eisai, Celltrion, PharmaKING and GC Wellbeing.

Funding Information:
Byoung Kuk Jang is a speaker for Gilead. He has received a research grant from PharmaKING, Novo Nordisk Pharma, Vaccitech and GC Wellbeing.

Funding Information:
This study was supported by the Korean Association for the Study of the Liver (KASL). This manuscript was reviewed by native speakers for English proof readings (Eworld Editing; KASL2104-01).

Funding Information:
Yong Kyun Cho is a speaker for Samil Pharm, Bukwang and DaeWoong. He has received a research grant from DaeWoong, Dong-A, Celltrion and Ildong.

Funding Information:
Seung Up Kim has served as an advisory committee member of Gilead Sciences, Bayer, Eisai, Novo Nordisk, and GreenCross. He is a speaker for Gilead Sciences, GSK, Bayer, Eisai, Abbvie, Echo-Sens, MSD, Eisai, Otsuka, Bristol-Myers Squibb, Yuhan, Samil Pharm, Ildong, Celltrion, PharmaKING, DaeWoong, Samjin, DongA, Hanmi, BuKwang, Echme medical, Hanwha, Sysmax, and ChongKunDang. He has also received a research grant from Ab-bvie, Bristol-Myers Squibb, ChongKunDang, DaeWoong, Hanmi, Samil Pharm, and Echme Medical.

All Science Journal Classification (ASJC) codes

Hepatology
Molecular Biology

Access to Document

10.3350/cmh.2021.0178

Cite this

Kang, S. H., Lee, H. W., Yoo, J. J., Cho, Y., Kim, S. U., Lee, T. H., Jang, B. K., Kim, S. G., Ahn, S. B., Kim, H., Jun, D. W., Choi, J. I., Song, D. S., Kim, W., Jeong, S. W., Kim, M. Y., Koh, H., Jeong, S., Lee, J. W., & Cho, Y. K. (2021). KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clinical and Molecular Hepatology, 27(3), 363-401. https://doi.org/10.3350/cmh.2021.0178

@article{5450a32272d840daaec326fabf996596,

title = "KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease",

author = "Kang, {Seong Hee} and Lee, {Hye Won} and Yoo, {Jeong Ju} and Yuri Cho and Kim, {Seung Up} and Lee, {Tae Hee} and Jang, {Byoung Kuk} and Kim, {Sang Gyune} and Ahn, {Sang Bong} and Haeryoung Kim and Jun, {Dae Won} and Choi, {Joon Il} and Song, {Do Seon} and Won Kim and Jeong, {Soung Won} and Kim, {Moon Young} and Hong Koh and Sujin Jeong and Lee, {Jin Woo} and Cho, {Yong Kyun}",

note = "Funding Information: Sang Bong Ahn has received grants from Hanwha, Samjin, Il-dong, and Hanmi. Funding Information: Tae Hee Lee is a speaker for Abbvie, Gilead, Samil Pharm and Yuhan. He has received a research grant from Eisai, Celltrion, PharmaKING and GC Wellbeing. Funding Information: Byoung Kuk Jang is a speaker for Gilead. He has received a research grant from PharmaKING, Novo Nordisk Pharma, Vaccitech and GC Wellbeing. Funding Information: This study was supported by the Korean Association for the Study of the Liver (KASL). This manuscript was reviewed by native speakers for English proof readings (Eworld Editing; KASL2104-01). Funding Information: Yong Kyun Cho is a speaker for Samil Pharm, Bukwang and DaeWoong. He has received a research grant from DaeWoong, Dong-A, Celltrion and Ildong. Funding Information: Seung Up Kim has served as an advisory committee member of Gilead Sciences, Bayer, Eisai, Novo Nordisk, and GreenCross. He is a speaker for Gilead Sciences, GSK, Bayer, Eisai, Abbvie, Echo-Sens, MSD, Eisai, Otsuka, Bristol-Myers Squibb, Yuhan, Samil Pharm, Ildong, Celltrion, PharmaKING, DaeWoong, Samjin, DongA, Hanmi, BuKwang, Echme medical, Hanwha, Sysmax, and ChongKunDang. He has also received a research grant from Ab-bvie, Bristol-Myers Squibb, ChongKunDang, DaeWoong, Hanmi, Samil Pharm, and Echme Medical.",

year = "2021",

month = jul,

doi = "10.3350/cmh.2021.0178",

language = "English",

volume = "27",

pages = "363--401",

journal = "Clinical and molecular hepatology",

issn = "2287-2728",

publisher = "Korean Association for the Study of the Liver",

number = "3",

}

Kang, SH, Lee, HW, Yoo, JJ, Cho, Y, Kim, SU, Lee, TH, Jang, BK, Kim, SG, Ahn, SB, Kim, H, Jun, DW, Choi, JI, Song, DS, Kim, W, Jeong, SW, Kim, MY, Koh, H, Jeong, S, Lee, JW & Cho, YK 2021, 'KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease', Clinical and Molecular Hepatology, vol. 27, no. 3, pp. 363-401. https://doi.org/10.3350/cmh.2021.0178

TY - JOUR

T1 - KASL clinical practice guidelines

T2 - Management of nonalcoholic fatty liver disease

AU - Kang, Seong Hee

AU - Lee, Hye Won

AU - Yoo, Jeong Ju

AU - Cho, Yuri

AU - Kim, Seung Up

AU - Lee, Tae Hee

AU - Jang, Byoung Kuk

AU - Kim, Sang Gyune

AU - Ahn, Sang Bong

AU - Kim, Haeryoung

AU - Jun, Dae Won

AU - Choi, Joon Il

AU - Song, Do Seon

AU - Kim, Won

AU - Jeong, Soung Won

AU - Kim, Moon Young

AU - Koh, Hong

AU - Jeong, Sujin

AU - Lee, Jin Woo

AU - Cho, Yong Kyun

N1 - Funding Information: Sang Bong Ahn has received grants from Hanwha, Samjin, Il-dong, and Hanmi. Funding Information: Tae Hee Lee is a speaker for Abbvie, Gilead, Samil Pharm and Yuhan. He has received a research grant from Eisai, Celltrion, PharmaKING and GC Wellbeing. Funding Information: Byoung Kuk Jang is a speaker for Gilead. He has received a research grant from PharmaKING, Novo Nordisk Pharma, Vaccitech and GC Wellbeing. Funding Information: This study was supported by the Korean Association for the Study of the Liver (KASL). This manuscript was reviewed by native speakers for English proof readings (Eworld Editing; KASL2104-01). Funding Information: Yong Kyun Cho is a speaker for Samil Pharm, Bukwang and DaeWoong. He has received a research grant from DaeWoong, Dong-A, Celltrion and Ildong. Funding Information: Seung Up Kim has served as an advisory committee member of Gilead Sciences, Bayer, Eisai, Novo Nordisk, and GreenCross. He is a speaker for Gilead Sciences, GSK, Bayer, Eisai, Abbvie, Echo-Sens, MSD, Eisai, Otsuka, Bristol-Myers Squibb, Yuhan, Samil Pharm, Ildong, Celltrion, PharmaKING, DaeWoong, Samjin, DongA, Hanmi, BuKwang, Echme medical, Hanwha, Sysmax, and ChongKunDang. He has also received a research grant from Ab-bvie, Bristol-Myers Squibb, ChongKunDang, DaeWoong, Hanmi, Samil Pharm, and Echme Medical.

PY - 2021/7

Y1 - 2021/7

UR - http://www.scopus.com/inward/record.url?scp=85110087905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85110087905&partnerID=8YFLogxK

U2 - 10.3350/cmh.2021.0178

DO - 10.3350/cmh.2021.0178

M3 - Article

C2 - 34154309

AN - SCOPUS:85110087905

SN - 2287-2728

VL - 27

SP - 363

EP - 401

JO - Clinical and molecular hepatology

JF - Clinical and molecular hepatology

IS - 3

ER -

KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease

Bibliographical note

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this